MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "MAO-B inhibitors"

  • 2018 International Congress

    Efficacy and safety of Rasagiline in treatment of gait disturbances in dementia with Lewy bodies

    A. Chimagomedova, O. Levin, M. Anikina, I. Ayzenberg (Moscow, Russian Federation)

    Objective: We aimed to investigate the efficacy and safety of rasagiline in addition to levodopa in patients with dementia with Lewy bodies (DLB). Background: Management…
  • 2018 International Congress

    Safinamide add-on therapy increases ON time without dyskinesia in fluctuating Parkinson’s Disease (PD) patients with moderate to severe dyskinesia

    V. Tubazio, C. Cattaneo, E. Bonizzoni, C. Keywood (Bresso (Milan), Italy)

    Objective: This post-hoc analysis examined safinamide efficacy for providing dyskinesia-free ON time in LID patients. Background: Safinamide has both dopaminergic and glutamate modulating activity. The…
  • 2018 International Congress

    Evaluation of the interaction between safinamide and opicapone in Parkinson’s disease patients with fluctuations

    J. Garcia-Caldentey, MA. Prats-Sedano, I. Legarda-Ramirez, E. Estelrich-Peyret, B. Vives-Pastor, PJ. Garcia (Palma de Mallorca, Spain)

    Objective: To describe and to evaluate a Balearic ongoing Parkinson's disease (PD) Project to evaluate the efficacy and tolerance of the interaction between safinamide and…
  • 2018 International Congress

    Safinamide effect in patients with Parkinson’s disease and deep brain stimulation

    F. Mancini, A. Di Fonzo, G. Lazzeri, L. Borellini, V. Silano, M. Lacerenza, C. Comi (Milan, Italy)

    Objective: Aim of this retrospective study is to evaluate safety and efficacy of safinamide in the treatment of motor complications in patients with Parkinson’s Disease…
  • 2018 International Congress

    Use of safinamide: A clinical practice review of 2 year experience

    C. Borrue-Fernandez (San Sebastian Reyes, Spain)

    Objective: Review the clinical use, efectivity and side efects in a population based cohort. Background: Safinamide is an oral, once a day adjunctive therapy for…
  • 2018 International Congress

    Anti-glutamatergic effect of safinamide in Parkinson’s Disease: A TMS study

    A. Guerra, A. Suppa, V. D'Onofrio, F. Di Stasio, F. Asci, G. Fabbrini, A. Berardelli (Rome, Italy)

    Objective: To test the effect of safinamide, at the doses of 50 and 100 mg/day, on primary motor cortex (M1) excitability and glutamatergic neurotransmission in…
  • 2017 International Congress

    The SYNAPSES study  (StudY to observe SafiNAmide in clinical Practice during the firSt post-commErcialization phaSe): methodology and results from the European feasibility survey

    G. Camattari, G. Abbruzzese, W. Jost, J. Kulisevsky, V. Tubazio, L. Simoni, The SYNAPSES investigators (Bresso, Italy)

    Objective: Here we present the design of a Drug Utilization Study of safinamide in the first post-commercialization phase and report results of the study feasibility…
  • 2017 International Congress

    Safinamide improves both motor and non-motor symptoms in fluctuating Parkinson’s Disease patients.

    C. Cattaneo (Bresso (Milan), Italy)

    Objective: To investigate the efficacy of safinamide, compared to placebo, as add-on therapy to stable doses of levodopa, on both motor and non-motor symptoms in…
  • 2016 International Congress

    Long-term efficacy of safinamide on mood in Parkinsonian patients with fluctuations

    C. Cattaneo, E. Mueller, M. Sardina (Bresso, Italy)

    Objective: The present post-hoc analysis of the results of two pivotal trials (016 and 018) investigated the effects of safinamide 100 mg/day on mood in…
  • 2016 International Congress

    Implications of direct and indirect costs in health-related quality of life in Parkinson’s disease: A cross-sectional study in Mexico

    M. Rodríguez-Violante, A. Jorge de Saráchaga, A. Cervantes-Arriaga, H. Soto-Molina, M. Márquez-Cruz (Mexico City, Mexico)

    Objective: To evaluate the association of direct and indirect costs of Parkinson's disease (PD) and health-related quality of life (HRQoL) in a Mexican population. Background:…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • #25676 (not found)
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Effect of marijuana on Essential Tremor: A case report
    • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley